Agendia
PrivateLast Round
VC Round
Jul 25, 2018
Total Funding Raised
$149.65M
Momentum Score
25 /100
Company Overview
Agendia is a commercial-stage precision oncology company that provides genomic diagnostic and information solutions to aid physicians in making optimized decisions for breast cancer patients. The company's primary products, MammaPrint and BluePrint, form a platform that uses genomic profiling to classify personalized breast cancer types and guide treatment. MammaPrint is an FDA-cleared test that assesses the risk of breast cancer recurrence. Agendia was founded in 2003 and has headquarters in Irvine, California, and Amsterdam, Netherlands. The company is focused on expanding its commercial presence globally and continues to invest in research and development, including large-scale studies like the FLEX Study.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Medical Devices, Healthcare Analytics
Business Model
B2B2C
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Agendia Comps
Public and private peers based on sector, stage, and business model.
Agendia Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jul 25, 2018 | ||||
| Grant | Dec 16, 2015 | ||||
| Debt | Mar 14, 2014 | ||||
| Private Equity | May 31, 2012 | ||||
| Series E | Sep 22, 2009 | ||||
Series D | Aug 29, 2007 |
Key People
Founding team and executive leadership
Agendia Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Norgine Ventures | Debt |
| Gilde Investment Management | Series A |
| Korys | Private Equity |
| ING Corporate Investments | Series E, Private Equity |
| Gilde Healthcare | Series E, Private Equity, Series C |
| The Van Herk Group | Private Equity |
| Global Life Science Ventures | Series A, Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 20, 2026
MammaPrint test recognized in updated NCCN guidelines for breast cancer treatment.
- Oct 15, 2025
Uses Glidian platform for prior authorizations.
Agendia Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Agendia's valuation, stock price, and market status.
